Samsung Electronics Co. Ltd et al. v. Maxell, Ltd.

IPR2024-00777

Maxell seeks Director Review of the PTAB’s decision to institute Samsung’s IPR against U.S. Patent 11,017,815, alleging abuse of discretion on public‑accessibility findings, prior‑art status, and burden‑shifting. The petition also raises policy concerns over multiple petitions on the same patent.

Jurisdiction
US PTAB
Case Number
IPR2024-00777
Decision Date
19 April 2024
Filing Date
19 April 2024

Detailed Summary

In a Request for Director Review, Maxell, Ltd. challenges the PTAB’s institution of Samsung Electronics’ inter partes review of U.S. Patent 11,017,815, which covers a digital video‑playlist management system. Maxell contends the Board erred by finding the WinTV manual publicly accessible without sufficient evidence, by failing to properly assess whether the Wong reference qualifies as prior art, and by improperly shifting the burden of showing non‑analogous art to the patent owner. Additionally, Maxell argues that filing two separate petitions against the same patent violates PTAB policy on fairness and efficiency. The petition urges the Director to overturn the institution decision, highlighting both factual and policy‑based errors.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co. Ltd et al. vs Maxell, Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-01369

Samsung Electronics Co., Ltd et al.vsSecure Wi-Fi LLC

Samsung has filed a Request for Director Review to overturn a PTAB discretionary denial that applied retroactively after the Vidal memo was rescinded. The petition argues due‑process violations and arbitrary weighting of Fintiv factors. Samsung seeks to submit a Sotera stipulation and have the institution decision vacated.

patentIPR2025-01269

Fresenius Kabi SwissBiosim, GmbH et al.vsRegeneron Pharmaceuticals, Inc.

Fresenius Kabi SwissBiosim petitions the PTAB to invalidate claims 1‑11 of Regeneron’s aflibercept eye‑drug patent, arguing anticipation and obviousness based on earlier clinical studies and publications.

patentIPR2025-00864

Taiwan Semiconductor Manufacturing Company, Ltd. et al.vsMarlin Semiconductor Ltd. et al.

An email from the PTAB Director confirms receipt of Director Review requests for IPR2025-00864 and IPR2025-00865, outlining a 15‑page response limit and prohibiting new evidence. The patent owner must file its response within five business days.

patentIPR2026-00098

Google LLCvsSecure Communication Technologies, LLC

Google has filed an IPR petition seeking to invalidate Secure Communication Technologies' ’736 patent covering server‑mediated data exchange between wireless devices, relying on Eagle and Mgrdechian prior art.

patentIPR2025-00290

Google LLC et al.vsPegasus Wireless Innovation LLC

Google and a consortium of carriers have filed an IPR petition seeking to invalidate U.S. Patent 10,721,118, which covers dual‑connectivity methods for user equipment. The petition relies on the Futaki publication and 3GPP standards to argue anticipation and obviousness of all 15 claims.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call